文献速递头颈部肿瘤放疗放疗物理与技术

DAHANCA 19 试验头颈部鳞癌放疗质量保证分析

Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial.
PubMed 文献 · Radiother Oncol · 2025-08-16

本研究对 DAHANCA 19 随机 III 期试验中 608 例头颈部鳞癌患者的完整放疗数据集进行集中质量保证分析,将剂量参数与 DAHANCA RTQA 指南比较并分类为无、次要或重大偏差。

要点

  • 重大偏差中 12 例在实验组、3 例在对照组(p=0.02)。
  • 重大偏差未降低局部区域或疾病特异性生存。

核心结论

  • DAHANCA 19 的治疗计划良好遵循国家指南,无证据表明放疗质量保证受损影响该试验结论。

研究设计与样本

  • 对 DAHANCA 19 随机 III 期试验中 608 例患者的完整放疗数据集进行集中质量保证分析,提取原发靶区、脊髓和脑干剂量及总治疗时间等参数。

主要发现

  • 608 例可分析患者中,118 例有 1 个次要偏差、20 例有 2 个、2 例有 3 个次要偏差。
  • 重大偏差中 12 例在实验组、3 例在对照组(p=0.02)。
  • 多数重大偏差被认为临床不可避免,不视为临床实践违规。
  • 有重大偏差的患者局部区域或疾病特异性生存未劣于无偏差者,但总生存显著更差且不归因于放疗。

关键数值与推荐

  • 放疗质量保证参数与 DAHANCA RTQA 指南比较,分类为无偏差、次要偏差或重大偏差。

临床怎么用

  • 头颈部鳞癌放疗应遵循国家质量保证指南,集中质量保证可识别偏差但多数重大偏差临床不可避免。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The current study investigates the radiotherapy quality assurance (QA) of the DAHANCA 19 randomised phase III trial comparing standard chemo-radiotherapy with and without Zalutumumab. MATERIAL AND METHODS: The complete radiotherapy datasets for 608 patients were collected centrally. QA parameters were extracted, including dose to the primary target volume, spinal cord and brainstem, and overall treatment time. These parameters were compared to DAHANCA RTQA guidelines and categorised into no, minor or major deviations. RESULTS: Among the 608 patients eligible for analyses, 118 had one minor deviation, 20 had two minor, and two had three minor deviations. Fifteen patients (2.5 %) had major deviations, with 13 related to overall treatment time or high-dose target volume coverage. Of the major deviations, 12 were in the experimental arm, and 3 were in the control arm (p = 0.02). Most major deviations were deemed clinically unavoidable and, therefore, not considered violations of clinical practice. There was no difference in outcomes between patients with minor deviations and those without deviations, aligning with current definitions and guidelines. Patients with major deviations did not have inferior loco-regional or disease-specific survival compared to those without deviations. However, they had significantly worse survival, which was not attributed to radiotherapy. CONCLUSIONS: The treatment plans in DAHANCA 19 adhered well to national guidelines. Most major deviations were observed in the experimental arm but did not affect the local treatment control. No indication that compromised RT-QA affected the conclusions of DAHANCA 19 was found.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hansen CR, Samsøe E, Smulders B, et al. Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial. Radiother Oncol. 2025. PMID: 40825443. doi:10.1016/j.radonc.2025.111096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。